JP2007536282A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007536282A5 JP2007536282A5 JP2007511768A JP2007511768A JP2007536282A5 JP 2007536282 A5 JP2007536282 A5 JP 2007536282A5 JP 2007511768 A JP2007511768 A JP 2007511768A JP 2007511768 A JP2007511768 A JP 2007511768A JP 2007536282 A5 JP2007536282 A5 JP 2007536282A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- bone
- growth hormone
- mammal
- estrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 25
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 208000020084 Bone disease Diseases 0.000 claims 6
- 102000002265 Human Growth Hormone Human genes 0.000 claims 5
- 108010000521 Human Growth Hormone Proteins 0.000 claims 5
- 239000000854 Human Growth Hormone Substances 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 5
- 210000000988 bone and bone Anatomy 0.000 claims 5
- 102000018997 Growth Hormone Human genes 0.000 claims 3
- 108010051696 Growth Hormone Proteins 0.000 claims 3
- 239000000122 growth hormone Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 claims 2
- 229930003316 Vitamin D Natural products 0.000 claims 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 2
- 229930003448 Vitamin K Natural products 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 229910052791 calcium Inorganic materials 0.000 claims 2
- 239000011575 calcium Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940011871 estrogen Drugs 0.000 claims 2
- 239000000262 estrogen Substances 0.000 claims 2
- 230000001076 estrogenic effect Effects 0.000 claims 2
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims 2
- 235000008696 isoflavones Nutrition 0.000 claims 2
- 229960004488 linolenic acid Drugs 0.000 claims 2
- 230000004066 metabolic change Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 235000019166 vitamin D Nutrition 0.000 claims 2
- 239000011710 vitamin D Substances 0.000 claims 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 2
- 235000019168 vitamin K Nutrition 0.000 claims 2
- 239000011712 vitamin K Substances 0.000 claims 2
- 150000003721 vitamin K derivatives Chemical class 0.000 claims 2
- 229940046008 vitamin d Drugs 0.000 claims 2
- 229940046010 vitamin k Drugs 0.000 claims 2
- OQPAZKMGCWPERI-GUBZILKMSA-N Arg-Ser-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O OQPAZKMGCWPERI-GUBZILKMSA-N 0.000 claims 1
- PQHYZJPCYRDYNE-QWRGUYRKSA-N Cys-Gly-Phe Chemical compound [H]N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O PQHYZJPCYRDYNE-QWRGUYRKSA-N 0.000 claims 1
- 208000013558 Developmental Bone disease Diseases 0.000 claims 1
- RAUDKMVXNOWDLS-WDSKDSINSA-N Glu-Gly-Ser Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O RAUDKMVXNOWDLS-WDSKDSINSA-N 0.000 claims 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 1
- UILIPCLTHRPCRB-XUXIUFHCSA-N Leu-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)N UILIPCLTHRPCRB-XUXIUFHCSA-N 0.000 claims 1
- 208000002720 Malnutrition Diseases 0.000 claims 1
- 208000029725 Metabolic bone disease Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000010191 Osteitis Deformans Diseases 0.000 claims 1
- 206010049088 Osteopenia Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000027868 Paget disease Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010072610 Skeletal dysplasia Diseases 0.000 claims 1
- LMSBRIVOCYOKMU-NRPADANISA-N Val-Gln-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N LMSBRIVOCYOKMU-NRPADANISA-N 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 235000013617 genetically modified food Nutrition 0.000 claims 1
- 238000001631 haemodialysis Methods 0.000 claims 1
- 230000000322 hemodialysis Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 230000037356 lipid metabolism Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 230000004130 lipolysis Effects 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 230000001071 malnutrition Effects 0.000 claims 1
- 235000000824 malnutrition Nutrition 0.000 claims 1
- 208000027202 mammary Paget disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000015380 nutritional deficiency disease Diseases 0.000 claims 1
- 230000000010 osteolytic effect Effects 0.000 claims 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 claims 1
- 230000035935 pregnancy Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2004902388A AU2004902388A0 (en) | 2004-05-04 | Methods for preventing or treating bone disorders | |
| AU2004902388 | 2004-05-04 | ||
| PCT/AU2005/000638 WO2005105132A1 (en) | 2004-05-04 | 2005-05-04 | Methods for preventing or treating bone disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007536282A JP2007536282A (ja) | 2007-12-13 |
| JP2007536282A5 true JP2007536282A5 (cg-RX-API-DMAC7.html) | 2008-06-26 |
| JP4931802B2 JP4931802B2 (ja) | 2012-05-16 |
Family
ID=35241438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007511768A Expired - Fee Related JP4931802B2 (ja) | 2004-05-04 | 2005-05-04 | 骨障害を予防または治療するための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8008433B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1755637B8 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4931802B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN1950103B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2005237187B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2564169C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2391853T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005105132A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110092448A1 (en) * | 2005-08-02 | 2011-04-21 | Metabolic Pharmaceuticals Limited | Peptide Conjugate for Oral Delivery of Hydrophilic Peptide Analgesics |
| WO2007068039A1 (en) * | 2005-12-12 | 2007-06-21 | Metabolic Pharmaceuticals Limited | Treatment of weight gain in estrogen deficient mammals |
| ES2764106T3 (es) * | 2011-12-09 | 2020-06-02 | Metabolic Pharmaceuticals Pty Ltd | Uso de fragmentos de la hormona del crecimiento |
| IT202100002228A1 (it) * | 2021-02-02 | 2022-08-02 | Univ Degli Studi Milano | Composizione per ridurre gli squilibri metabolici conseguenti all'insufficienza ovarica |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995002610A1 (en) * | 1993-07-13 | 1995-01-26 | Syntex (U.S.A.) Inc. | Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis |
| BR9811755A (pt) * | 1997-09-08 | 2000-08-29 | Metabolic Pharmaceutical Ltd | Peptìdeo, processo para o tratamento da obesidade em um animal, uso de um peptìdeo, e, composição farmacêutica |
| ES2219368T3 (es) | 1999-07-13 | 2004-12-01 | MERCK & CO., INC. | Amidoespiropiperidinas que promueven la liberacion de la hormona de crecimiento. |
| AUPQ387599A0 (en) | 1999-11-05 | 1999-12-02 | Metabolic Pharmaceuticals Limited | Product and method for control of obesity |
| WO2002016589A2 (en) * | 2000-08-21 | 2002-02-28 | Millennium Pharmaceuticals, Inc. | Human abc transporter family member and uses thereof |
| CA2500665A1 (en) | 2002-10-07 | 2004-04-22 | Zymogenetics, Inc. | Methods of regulating body weight |
-
2005
- 2005-05-04 ES ES05738284T patent/ES2391853T3/es not_active Expired - Lifetime
- 2005-05-04 WO PCT/AU2005/000638 patent/WO2005105132A1/en not_active Ceased
- 2005-05-04 US US11/579,124 patent/US8008433B2/en not_active Expired - Fee Related
- 2005-05-04 CA CA2564169A patent/CA2564169C/en not_active Expired - Fee Related
- 2005-05-04 JP JP2007511768A patent/JP4931802B2/ja not_active Expired - Fee Related
- 2005-05-04 CN CN2005800144115A patent/CN1950103B/zh not_active Expired - Fee Related
- 2005-05-04 EP EP05738284A patent/EP1755637B8/en not_active Expired - Lifetime
- 2005-05-04 AU AU2005237187A patent/AU2005237187B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP860A (en) | Dipeptide compounds which are growth hormone secretegoques. | |
| JP5000848B2 (ja) | グレリン含有医薬組成物 | |
| CN101189021B (zh) | 用于控制、预防和治疗肥胖和进食障碍的组合物和方法 | |
| JP4173914B2 (ja) | Ｏｂ蛋白組成物を用いる非脂肪組織重増加方法 | |
| US8602998B2 (en) | Use of relaxin to increase arterial compliance | |
| JP5956715B2 (ja) | Ｅｔｂ受容体アゴニストを用いた脳卒中または脳血管障害の治療方法 | |
| US7485620B2 (en) | Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof | |
| CZ298292B6 (cs) | Vodný farmaceutický prostředek s obsahem růstového hormonu a jeho použití | |
| CN1878555A (zh) | 包含n－(3－甲氧基－5－甲基吡嗪－2－基)－2－(4－[1,3,4－噁二唑－ 2－基]苯基)吡啶－3－磺酰胺与lhrh类似物和/或二膦酸盐的联合药物 | |
| US4652547A (en) | Pharmaceutical formulations comprising human insulin and human proinsulin | |
| PT1397156E (pt) | Método para a administração oral da hormona paratireóide ( pth ). | |
| US20020094951A1 (en) | Dental remedies containing pth | |
| JP2007536282A5 (cg-RX-API-DMAC7.html) | ||
| ES2980806T3 (es) | Combinación de análogos de la somatostatina con inhibidores de la 11-beta-hidroxilasa | |
| JP2012522727A (ja) | 大動脈線維症の治療のための組成物および方法 | |
| CA2559745C (en) | Use of relaxin to increase arterial compliance | |
| JP2003095974A (ja) | 骨形成を安全に促進させる医薬複合剤 | |
| GB2104380A (en) | Human proinsulin pharmaceutical formulations | |
| JP2007519669A (ja) | 脂肪異栄養症を治療するための方法及び組成物 | |
| JP5300943B2 (ja) | 骨形成を安全に促進させる医薬複合剤 | |
| EP0672420A1 (en) | Wound remedy | |
| WO2024209050A1 (en) | Gip activity modulators and orthostatic intolerance | |
| US20030207811A1 (en) | Method of treating retinopathy of prematurity using somatostatin analogs | |
| Hanssen et al. | EXTENDED EXPERIENCE WITH RECOMBINANT a-2b INTERFERON WITH OR WITHOUT HEPATIC ARTERY EMBOLIZATION IN THE TREATMENT OF MIDGUT CARCINOID TUMOURS | |
| JPH1192395A (ja) | Ｐｔｈを含有する歯科治療剤 |